Long-term Survival Benefit of Statin in Patients with Coronary Chronic Total Occlusion without Revascularization
Bum-Sung KIM; Jeong-Hoon YANG; Woo-Jin JANG; Young-Bin SONG; Joo-Yong HAHN; Jin-Ho CHOI; Ki-Hong CHOI; Sung-Hea KIM; Woo-Jung CHUN; Hyeon-Cheol GWON; Seung-Hyuk CHOI.
Journal of Korean Medical Science
; : e134-2018.
Artículo
en Inglés
| WPRIM | ID: wpr-714078
BACKGROUND:
Limited data are available on the efficacy of statin therapy in stable ischemic heart disease with chronic total occlusion (CTO) without revascularization. We investigated whether statin therapy could be beneficial in stable patients with CTO without revascularization.METHODS:
From March 2003 to February 2012, 2,024 patients with at least one CTO were enrolled in a retrospective, single-center registry; 664 of these patients were managed conservatively without an initial revascularization strategy. Among them, we excluded CTO cases involving acute coronary syndrome, in-hospital death or incomplete data and classified 551 patients into statin (n = 369) and non-statin (n = 182) groups according to use of statin at discharge. Propensity score matching analysis was also performed in 148 pairs. The primary outcome was cardiac death.RESULTS:
The median overall follow-up duration was 45.7 months (interquartile range 19.9–70.5 months). Cardiac death occurred in 22 patients (6.0%) in the statin group vs. 24 patients (13.2%) in the non-statin group (P 70 years, renal insufficiency, prior myocardial infarction, left ventricular ejection fraction < 40%, proximal-to-mid CTO location, and no use of statin in CTO patients.CONCLUSION:
Statin therapy at discharge may be associated with a reduction in long-term cardiac mortality in stable CTO patients without revascularization.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados